Skip to main content

Table 1 Numbers and proportions (%) of patients with seropositive rheumatoid arthritis (RA), seronegative RA and undifferentiated arthritis using various anti-rheumatic drugs and drug combination strategies by the end of the first month after arthritis diagnosis

From: First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study

 Seropositive rheumatoid arthritis
N = 4998
Seronegative rheumatoid arthritis
N = 2340
Undifferentiated arthritis
N = 2433
p-value
Females N (%)3349 (67.0)1584 (67.7)1650 (67.8) 
Mean age at diagnosis, years (SD)58 (15)56 (17)49 (17) 
Combination strategies of DMARDs, N(%)
 Two DMARDs1684 (33.7)727 (31.1)395 (16.2)< 0.001
 Three DMARDs1118 (22.4)255 (10.9)77 (3.1)< 0.001
 MTX-based combination2489 (49.8)841 (35.9)390 (16.0)< 0.001
 FIN-RACo combination*1114 (22.3)253 (10.8)75 (3.1)< 0.001
  MTX + SSZ + HCQ + PRD922 (18.4)205 (8.8)52 (2.1) 
  MTX + SSZ + HCQ192 (3.8)48 (2.1)23 (0.9) 
Medications
 Methotrexate (MTX)3602 (72.1)1483 (63.4)1043 (42.9)< 0.001
  MTX per os3428 (68.6)1399 (59.8)949 (39.0) 
  MTX s.c.174 (3.5)84 (3.6)94 (3.9) 
 Sulfasalazine (SSZ)2059 (41.2)880 (37.6)1121 (46.1)< 0.001
 Hydroxychloroquine (HCQ)2272 (55.5)940 (40.2)472 (19.4)< 0.001
 Leflunomide51 (1.0)30 (1.3)23 (1)0.48
 Azathioprine29 (0.6)11 (0.5)14 (0.6)0.83
 Aurathiomalate9 (0.2)2 (0.1)2 (0.1)0.44
 Auranofin3 (0.1)1 (0.0)1 (0.0)0.95
 Cyclosporine1 (0.0)3 (0.1)6 (0.3)0.015
 Prednisolone (PRD)3025 (60.5)1352 (57.8)890 (36.6)< 0.001
 Self-injected biologics (all)41 (0.8)28 (1.2)17 (0.7)0.15
 Etanercept3 (0.06)11 (0.47)2 (0.08) 
 Adalimumab4 (0.08)6 (0.27)1 (0.04) 
 Certolizumab1 (0.02)0 (0)0 (0) 
 Golimumab3 (0.03)1 (0.04)0 (0) 
 Abatacept1 (0.02)0 (0)0 (0) 
 No antirheumatic medication401 (8.0)227 (9.7)300 (13.3)< 0.001
 Only prednisolone85 (1.7)63 (2.7)46 (1.9)0.61
  1. *FIN-RACo combination: Methotrexate (MTX), sulfasalazine (SSZ), and hydroxychloroquine (HCQ) often combined with low-dose prednisolone (PRD)